SCHEMBL16638794

SCHEMBL16638794

CCCC[N+](C)(C)CCOC(=O)CCSCCC[Si](OC)(OC)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
ACHE P22303 3/20 0.36
ADRA2A P08913 1/20 0.36
ADRA1A P35348 1/20 0.36
MAPT P10636 1/20 0.36
BLM P54132 1/20 0.36
DGKA P23743 1/20 0.35
PLA2G4B P0C869 1/20 0.34
RAD52 P43351 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
DNM1 Q05193 1/20 0.31
HTR2C P28335 1/20 0.30
PRKD3 O94806 1/20 0.30
PRKCG P05129 1/20 0.30
PRKCB P05771 1/20 0.30
PRKCA P17252 1/20 0.30
PRKCH P24723 1/20 0.30
PRKCI P41743 1/20 0.30
PRKCE Q02156 1/20 0.30
PRKCQ Q04759 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13260890 0.87 ADRA2A (0.50) LMNAACHEADRA2AADRA1AMAPT
SCHEMBL10178872 0.83 DGKA (0.38) ADRA2AADRA1AMAPTBLMDGKA
SCHEMBL16728063 0.79 DNM1 (0.43) DGKAPLA2G4BDNM1HTR2C
SCHEMBL2616693 0.79 MGLL (0.35) ACHEADRA2AADRA1ADGKAPLA2G4B
SCHEMBL2616655 0.78 PLA2G4B (0.39) LMNADGKAPLA2G4B
SCHEMBL10178702 0.77 ADRA2A (0.47) LMNAACHEADRA2AADRA1AMAPT
SCHEMBL2616695 0.77 PLA2G4B (0.38) LMNADGKAPLA2G4B
SCHEMBL16728123 0.76 DNM1 (0.47) BLMDNM1
SCHEMBL13789646 0.74 ENPP2 (0.34) DGKA
SCHEMBL10178848 0.74 TSHR (0.43) LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9954162-B2 Reactive ionic liquid, and ion-immobilized metal oxide particle, ion-immobilized elastomer, and transducer using same SUMITOMO RIKO COMPANY LIMITED (JP) 2018-04-24 US disclosed
EP-2860183-A9 REACTIVE IONIC LIQUID AND ION-IMMOBILIZED METAL OXIDE PARTICLES PRODUCED USING SAME, ION-IMMOBILIZED ELASTOMER, AND TRANSDUCER Sumitomo Riko Company Limited (JP) 2015-05-27 EP disclosed
US-20150137666-A1 REACTIVE IONIC LIQUID, AND ION-IMMOBILIZED METAL OXIDE PARTICLE, ION-IMMOBILIZED ELASTOMER, AND TRANSDUCER USING SAME SUMITOMO RIKO COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2860183-A1 REACTIVE IONIC LIQUID AND ION-IMMOBILIZED METAL OXIDE PARTICLES PRODUCED USING SAME, ION-IMMOBILIZED ELASTOMER, AND TRANSDUCER Sumitomo Riko Company Limited (JP) 2015-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150137666-A1 REACTIVE IONIC LIQUID, AND ION-IMMOBILIZED METAL OXIDE PARTICLE, ION-IMMOBILIZED ELASTOMER, AND TRANSDUCER USING SAME L1CAM, ITGA2B, AS3MT LMNA 876/4885ACHE 1425/4885ADRA2A 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.